Business
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a clinical trial TEL AVIV, Israel, April 04, 2023 (GLOBE NEWSWIRE) --
About this update from Scisparc Ltd.
[{"type":"text","content":"The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a clinical trial TEL AVIV, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the \"Company\" or \"SciSparc\"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome (“TS”). The Trial is titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”. The first clinical site to receive approval to initiate the trial is the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, under the leadership of Prof. Tanya Gurevich, Head of Movement Disorders Unit, Department of Neurology. The Company also intends to conduct the clinical trial in various sites including Yale Child Study Center, Yale School of Medicine, Connecticut, USA, under the leadership of Dr. Michael H. Bloch and Hannover Medical School, Hannover, Germany, under the leadership of Prof. Muller-Vahl, Department of Psychiatry. The launch of the clinical trial at Yale University is subject to approvals by the United States Food and Drug Administration and Yale University’s institutional review board and the launch of the clinical trial at Hannover Medical School is subject to approvals by the German Federal Institute for Drugs and Medical Devices. “We are thrilled to launch our Phase IIb Clinical Trial in Israel and start enrollment of patients suffering from Tourette Syndrome. This trial is a key milestone in SciSparc's pursuit of lower-dose, THC-based treatment that is potentially safer and more effective for patients than all the current available treatments,\" said Oz Adler, Chief Executive Officer of SciSparc. \"TS is estimated to affect 0.5-1% of the world's population, however the very few available treatments have limited efficacy and questionable safety. Based on previous results from our phase IIa trial conducted at Yale University, we believe our proprietary SCI-110 treatment has the potential to help TS patients around the world,\" Adler added. T...